Skip to main content
Brian Steingo, MD, Neurology, Boca Raton, FL

BrianSteingoMD

Neurology Boca Raton, FL

Neuroimmunology/Multiple Sclerosis

First Choice Neurology

Dr. Steingo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Steingo's full profile

Already have an account?

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineResidency, Neurology, 1978 - 1980
  • University of the Witwatersrand
    University of the WitwatersrandClass of 1971
  • University of the Witwatersrand
    University of the WitwatersrandBS, Microbiology, Biochemistry, 1968

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1980 - 2025
  • TX State Medical License
    TX State Medical License 1978 - 1999
  • SC State Medical License
    SC State Medical License 1978 - 1982
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient and physician reported outcomes in relapsing multiple sclerosis: p...  
    Calkwood, J., Cree, B., Crayton, H., Kantor, D., Steingo, B., Barbato,L., Hashmonay, R., Agashivala, N., McCague, K., Tenenbaum, N. and Edwards, K, BMC Neurology, 1/1/2014
  • Emerging challenges on the therapeutic landscape of multiple sclerosis: The managed care physician’s perspective and medical director’s perspective  
    Cree, B. A., Steingo, B., Journal of Managed Care Medicine, 1/1/2012

Abstracts/Posters

  • Real-world patient retention and satisfaction on fingolimod versus platform injectable disease-modifying therapies in early RRMS: results from PREFERMS
    Heidi Crayton, Brian Steingo, DeRen Huang, Xiangyi Meng, Lesley Schofield, Kristen Johnson, Nadia Tenenbaum on behalf of the PREFERMS investigators, Sunrise Medical Group, Neurology and Neuroscience Associates, Unity Health Network, Novartis Pharmaceuticals Corporation, 68th Congress of the American Academy of Neurology, Multiple locatoins, 1/1/2016
  • Patients of African Descent With Active RRMS Demonstrate Clinical and Radiologic Benefits With Alemtuzumab Over 5 Years
    Annette Okai, Keith R Edwards, Brian Steingo, David H Margolin, Sourav Santra, Mitzi Williams, 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), Multiple locatoins, 1/1/2016
  • No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-term Responders From CARE-MS II
    Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Brian Steingo, David H Margolin, Karthinathan Thangavelu, Gavin Giovannoni, Central Texas Neurology Consultants, First Medical Faculty, 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), Multiple locatoins, 1/1/2016
  • Join now to see all

Lectures

  • Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
    CMEducation Resources, LLC, Philadelphia, Pennsylvania - 4/27/2013
  • Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
    CMEducation Resources, LLC, New Orleans, Louisiana - 3/16/2013
  • Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
    CMEducation Resources, LLC, Baltimore, Maryland - 3/9/2013
  • Join now to see all

Professional Memberships